Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces
CGRP inhibitor use increased from 2018 to 2023. After CGRP inhibitor initiation, most patients had concomitant use with a different prophylactic migraine medication class, and some stopped use; migraine-related acute medication and healthcare use were lower (versus before). Findings provide a real-world description of the evolving landscape of CGRP inhibitor use in Canada.
Authors
- Marina Gabriela Birck (ORCID: https://orcid.org/0000-0003-3003-1839)
- Farnaz Amoozegar
- David Stock
- Khanh Dang Vu
- Grace W.C. Cheung
- Sasha Bernatsky
- Devin Manning
- Cristiano S. Moura
- Louis de Léséleuc
- Huong Luu
- Smriti Fernandez
- Jean-Luc Kaboré
- Scott Klarenbach
- Jason R. Randall
- Karen J.B. Martins
- Daniel J. Dutton
- Sandy Morrison
- Zhaoyu Liu
- Houssem Missaoui
Institutions
- Canadian Agency for Drugs and Technologies in Health (CA)
- Dalhousie University (CA)
- Canadian Institute for Health Information (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- South Health Campus (CA)
- McGill University Health Centre (CA)
- Institut National d'Excellence en Santé et en Services Sociaux (CA)
- McGill University (CA)
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1017/cjn.2025.10506
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47